Billy Dunn

Shares of Sarepta Therapeutics Inc (NASDAQ: SRPT) plunged 50 percent early Tuesday morning after a federal advisory panel voted that eteplirsen, its drug for the treatment of Duchenne muscular dystrophy (DMD), was not effective. The U.S. Food and Drug Administration voted 6-7 against the...